Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivoSim LabsFRA:4OR 28 EV-to-Revenue is 21.34 as of Sep. 13, 2026, which is 3% below its 10-year median of 21.93. GuruFocus rates FRA:4OR with a GF Score™ of 28/100 and a GF Value™ of €14.93. The stock has 6 warning signs investors should review. Among 963 Biotechnology companies, VivoSim Labs ranks worse than 68.43% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, VivoSim Labs's enterprise value is €2.07 Mil.
VivoSim Labs's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was €0.10 Mil. Therefore, VivoSim Labs's EV-to-Revenue for today is 21.34.
The historical rank and industry rank for VivoSim Labs's EV-to-Revenue or its related term are showing as below:
FRA:4OR'
s EV-to-Revenue Range Over the Past 10 Years
Min: -55.53 Med: 21.93 Max: 367.85
Current: 21.46
During the past 13 years, the highest EV-to-Revenue of VivoSim Labs was 367.85. The lowest was -55.53. And the median was 21.93.
FRA:4OR's EV-to-Revenue is ranked worse than 68.43% of 963
companies
in the Biotechnology industry
Industry Median: 8.49
vs FRA:4OR: 21.46
As of today (2026-09-13), VivoSim Labs's stock price is €3.492.
VivoSim Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.04. Therefore, VivoSim Labs's PS Ratio for today is 99.77.
VivoSim Labs's share price for today is €3.492.
VivoSim Labs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs EV-to-Revenue Related Terms
VivoSim Labs EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4OR vs SPRC, GOVX, SXTP: EV-to-Revenue Comparison
For the Biotechnology subindustry, VivoSim Labs's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs EV-to-Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's EV-to-Revenue falls into.
VivoSim Labs's current Enterprise Value is €2.07 Mil.
VivoSim Labs's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a EV-to-Revenue of 21.34 as of Sep. 13, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on VivoSim Labs and its competitors. This is near median its historical median of 21.93. According to the industry distribution chart, VivoSim Labs ranks #659 out of 963 companies in the Biotechnology industry, placing it in the top 68.4%.
Is VivoSim Labs' EV-to-Revenue too high?
VivoSim Labs' current EV-to-Revenue of 21.34 is near median its 10-year median of 21.93. The Biotechnology industry median EV-to-Revenue is 8.49. VivoSim Labs' value of 21.34 is 151.4% above this industry median. Based on the distribution chart, VivoSim Labs ranks #659 out of 963 companies in the Biotechnology industry, which is below the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' EV-to-Revenue compare to SPRC and GOVX?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #659 out of 963 companies for EV-to-Revenue. This places VivoSim Labs in the lower half of its industry. The industry median EV-to-Revenue is 8.49. VivoSim Labs' value of 21.34 is 151.4% above this benchmark. While the company's 10-year median is 21.93 vs. the industry median of 8.49, VivoSim Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Biotechnology company?
The median EV-to-Revenue among Biotechnology companies is 8.49, based on 963 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current EV-to-Revenue of 21.34 is 151.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on VivoSim Labs and its competitors. For the Biotechnology industry, the median EV-to-Revenue is 8.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current EV-to-Revenue is 21.34, which is near median its own 10-year median of 21.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current EV-to-Revenue of 21.34. The stock's GF Value™ is €14.93, compared to a current price of €3.49 — trading 76.6% below its estimated fair value. The current EV-to-Revenue is 21.34, which is near median its 10-year median of 21.93 and 151.4% above the Biotechnology industry median of 8.49. VivoSim Labs' overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current EV-to-Revenue is 21.34 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 76.6% below its estimated GF Value™ of €14.93.
Key valuation signals for FRA:4OR:
EV-to-Revenue: 21.34 (near median its 10-year median of 21.93)
GF Value™: €14.93 vs. price of €3.49 (76.6% below fair value)
Industry Position: 151.4% above the Biotechnology median (#659 of 963)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
28GF Score
Get the complete analysis for FRA:4OR
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
